We also discovered one highly specific humanized monoclonal antibody MLN1202 (clinical trial-Phase II) that interrupts MCP-1 binding to CCR2. These drugs (CCX915, CCX140-B, TAK779, and MLN 1202) have been used in the past in treatment of rheumatoid arthritis, diabetes mellitus, multiple sclerosis (139) and cardiovascular diseases with a modicum of success (140, 141) (Supplementary Table 7). This evidence concerns the gene CCR2 and cardiovascular disorder.